World News: 13:00 GMT Friday 12th October 2018. [Foamix, Ltd. via Globe Newswire via SPi World News]
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that data from its Phase 3 clinical trial, FX2017-22, which investigated FMX101 for the treatment of moderate-to-severe acne, will be presented at the Fall Clinical Dermatology Conference to be held October 18 – 21 at the Wynn Hotel in Las Vegas, Nevada.
The poster, which is entitled “ is expected to be presented during several plenary and scientific poster sessions throughout the conference. A copy of the poster will be available on the Foamix corporate website , simultaneous with its presentation at the conference.
As the company previously communicated, the Phase 3 study met both co-primary endpoints of (1) absolute change from baseline in inflammatory lesion count at Week 12, and (2) Investigator Global Assessment (“IGA”) treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from baseline. Results from both co-primary endpoints demonstrated highly statistically significant results for FMX101 vs vehicle, with p-values <0.0001. The favorable safety profile of FMX101 was consistent with that determined from the two prior Phase 3 studies of FMX101 in acne (FX2014-04 and FX2014-05).
Foamix uses its website (www.Foamix.com) as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor the Foamix website in addition to following its press releases, filings with the Securities & Exchange Commission (“SEC”), public conference calls, and webcasts.
Globe Newswire: 13:00 GMT Friday 12th October 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.